Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

Hoff, Katja von; Hinkes, Bernward; Gerber, Nicolas U.; Deinlein, Frank; Mittler, U; Urban, Christian; Benesch, Martin; Warmuth‐Metz, Monika; Soerensen, Niels; Zwiener, Isabella; Goette, H.; Schlegel, Paul G.; Pietsch, Torsten; Kortmann, Rolf Dieter; Kuehl, Joachim; Rutkowski, Stefan

doi:10.1016/j.ejca.2009.01.015

Cited by 172 publications

(98 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They found the 5-year survival rate for medulloblastoma and PNET increased over the study time period with 43.7 % in 1974-1978 to 62.8 % in 1999-2003, again similar to our data. The HIT 91 protocol for children over the age of 3 years with medulloblastoma had a 10-year overall survival of 91 % for patients with M0 disease, 70 % for patients with M1 disease and 42 % for patients with M2/3 disease [5]. The HIT-SIOP PNET 4 trial compared hyperfractionated to conventional radiotherapy for standard risk medulloblastoma and had a 5-year overall survival of 86 ± 2 % and an event free survival of 79 ± 2 % [6].…”

Section: Discussionmentioning

confidence: 99%

“…Other factors shown to influence survival include histological subtype, age at diagnosis, and therapy utilized. The majority of publications on survival of medulloblastoma describe results of clinical trials, which have stringent eligibility criteria that necessarily influence the survival data [5][6][7][8][9]. As well, the majority of medulloblastoma studies are for specific age ranges, usually over age 3 or under age 3, and not for the whole population of affected children.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive

et al. 2015

View full text Add to dashboard Cite

The treatment of medulloblastoma, the most common malignant brain tumor in children, has evolved over the last few decades. The objectives of this paper were to determine the survival of pediatric medulloblastoma in Canada, to determine if there has been an improvement in the survival rates between the years of 1990 and 2009, inclusive, and to determine prognostic factors for survival. All patients under the age of 18 years diagnosed with medulloblastoma from 1990 to 2009, inclusive, in Canada were included. Data collected included date of diagnosis, age at diagnosis, gender, stage, pathology, treatment, recurrence and current status. From these, survival rates were determined. Data were obtained on 628 eligible patients. The overall 5-year survival rate for the study time period was 69.2 ± 3.3 %. The survival rate increased during the interval of 1996-2000, then remained stable; 1990-1994: 60.2 ± 4.3 %; 1995-1999: 73.2 ± 3.5 %; 2000-2004: 68.8 ± 3.7 %; and 2005-2009: 72.1 ± 4.9 %, p = 0.05. Children over 14 years of age had a significantly better overall survival than those age 5-14 and those under 5 (85.7 ± 5.5 % vs 76.1 ± 2.7 % and 60.8 ± 3 % respectively, p = 0.001). Histologic medulloblastoma subtype and M stage of disease did not result in significant differences in survival. Despite changes in approaches to therapy, we demonstrate a steady survival rate for children with medulloblastoma after 1996. In our analyses, age over 14 years was associated with a higher survival rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive

et al. 2015

View full text Add to dashboard Cite

show abstract

“…After complete resection (R0, M0) of a medulloblastoma in a 5-year-old boy, chemotherapy and irradiation were performed according to the HIT-MED 80 protocol (24 Gy craniospinal, tumor boost 54.6 Gy) [17]. An atypical meningioma (WHO II) was diagnosed in the right post central area 12 years after irradiation as a SMN.…”

Section: Casesmentioning

confidence: 99%

“…After complete resection (R0, M0) of a medulloblastoma in a 1.5-yearold male infant, chemotherapy and irradiation were performed according to the HIT-MED 80 protocol [17] (25 Gy craniospinal, tumor boost add 45 Gy) at the age of 1.8 years. Eleven years after irradiation, multiple supratentorial and cerebellar meningiomas (WHO I) were diagnosed.…”

Section: Patientmentioning

confidence: 99%

See 1 more Smart Citation

Meningioma as second malignant neoplasm after oncological treatment during childhood

et al. 2012

View full text Add to dashboard Cite

A total of 38 patients (18 female/20 male) with childhood meningioma were recruited from the German registry HIT-Endo (1989-2009). In 5 cases meningioma occurred as second malignant neoplasm (SMN). Histologies were confirmed by reference assessment in all cases (SMN: 2 WHO I, 1 WHO II, 2 WHO III). The SMNs were diagnosed at a median age of 12.4 years with a median latency of 10.2 years after primary malignancy (PMN; 4 brain tumors, 1 lymphoblastic leukemia; median age at diagnosis 2.7 years). Meningioma occurred as SMN in the irradiated field of PMN (range 12-54 Gy). The outcome after treatment of SMN meningioma (surgery/irradiation) was favorable in terms of psychosocial status and functional capacity in 4 of 5 patients (1 death). We conclude that survivors of childhood cancer who were exposed to radiation therapy at young age harbor the risk of developing meningioma as a SMN at a particularly short latency period in case of high dose exposure.

show abstract

Radiotherapy Deferral in Medulloblastoma

Paulino

Jaboin

2016

JAMA Oncol

View full text Add to dashboard Cite

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

Cited by 172 publications

References 31 publications

Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive

Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive

Meningioma as second malignant neoplasm after oncological treatment during childhood

Radiotherapy Deferral in Medulloblastoma

Contact Info

Product

Resources

About